Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Exclusion Criteria

• •History or presence of central nervous system disease
• •Patients with a history of another primary cancer within 5 years
• •Prior chemotherapy for metastatic colorectal cancer
• •Prior full field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks before entry to study
• •Major surgery within 4 weeks or minor surgery within 2 weeks before entry to study
• •Investigational drugs within 4 weeks before entry to study
• •Prior therapy with anti-VEGF agents
• •Any prior therapy with oxaliplatin or allergy to platinum-containing drugs
• •Peripheral neuropathy with functional impairment
• •Female patients who are pregnant or breast feeding
• •Any severe or uncontrolled medical conditions which could prevent participation in study
• •Patients who are taking Coumadin